Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).

Trial Profile

Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms GET-C
  • Sponsors Schering-Plough
  • Most Recent Events

    • 28 Jul 2009 Actual patient number (146) added as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Status change from suspended to discontinued, as reported by clinicaltrials.gov.
    • 17 Jan 2008 The expected completion date for this trial is now 1 Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top